Anatomic Stage IV Breast Cancer AJCC v8 Clinical Trial
Official title:
Evaluation Of Benefits of The Portable Scalp Cooling System (PSCS) in Metastatic Breast Cancer Patients on Taxane-Based Chemotherapy
This clinical trial evaluates the benefits of a portable scalp cooling system (PSCS) for improving chemotherapy-induced hair loss in patients with breast cancer that has spread to other places in the body (metastatic) and are undergoing taxane-based chemotherapy. The PSCS is a new system designed to reduce chemotherapy induced hair loss. The PSCS is designed as a portable unit, allowing patients to leave the infusion center after chemotherapy is completed and finish scalp cooling at home. PSCS may help improve chemotherapy-induced hair loss in patients with metastatic breast cancer receiving chemotherapy.
PRIMARY OBJECTIVE: I. Measure efficacy of scalp cooling for patients undergoing taxane based chemotherapy for metastatic breast cancer. SECONDARY OBJECTIVES: I. Assess safety of PSCS in treating patients with metastatic breast cancer. II. Assess burden on nurses and infusion center team of patients using the PSCS. III. Assess tolerability of PSCS. IV. Assess hair loss and recovery as assessed by the patient. V. Assess patient quality of life and satisfaction with treatment. OUTLINE: Patients undergo scalp cooling using the PSCS 30 minutes before, during, and for up to 2 hours after completion of chemotherapy for 6 chemotherapy sessions. After completion of study, patients are followed up for 1 year. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT05673200 -
Testing the Addition of an Anti-cancer Drug, ASTX727 (Cedazuridine, Decitabine), to Chemotherapy (Paclitaxel) and Immunotherapy (Pembrolizumab) for Metastatic Triple-Negative Breast Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT03218826 -
PI3Kbeta Inhibitor AZD8186 and Docetaxel in Treating Patients Advanced Solid Tumors With PTEN or PIK3CB Mutations That Are Metastatic or Cannot Be Removed by Surgery
|
Phase 1 | |
| Recruiting |
NCT04521764 -
A Vaccine (MV-s-NAP) for the Treatment of Patients With Invasive Metastatic Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT03723928 -
S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer
|
N/A | |
| Suspended |
NCT03737695 -
Clinical Information and Biospecimen Collection From Patients With Recurrent or Stage IV Breast Cancer
|
||
| Active, not recruiting |
NCT04316117 -
Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study
|
Phase 2 | |
| Not yet recruiting |
NCT04529044 -
177Lu-DOTATATE for the Treatment of Stage IV or Recurrent Breast Cancer
|
Phase 2 | |
| Recruiting |
NCT04862585 -
Safely Stopping Pre-medications in Patients With Breast Cancer Who Are Receiving Paclitaxel
|
Phase 2/Phase 3 | |
| Completed |
NCT00338728 -
Letrozole and Imatinib Mesylate in Treating Postmenopausal Participants With Estrogen or Progesterone Positive Metastatic Breast Cancer
|
Phase 2 | |
| Withdrawn |
NCT05967286 -
Olaparib and Alpelisib for Treatment of Metastatic Breast Cancer, A ComboMATCH Treatment Trial
|
Phase 2 | |
| Recruiting |
NCT04673448 -
Niraparib and TSR-042 for the Treatment of BRCA-Mutated Unresectable or Metastatic Breast, Pancreas, Ovary, Fallopian Tube, or Primary Peritoneal Cancer
|
Phase 1 | |
| Active, not recruiting |
NCT05081492 -
CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer
|
Phase 1 | |
| Recruiting |
NCT05318469 -
Ivermectin and Balstilimab for the Treatment of Metastatic Triple Negative Breast Cancer
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05539365 -
Dendritic Cell-Based Treatment Plus Immunotherapy for the Treatment of Metastatic or Unresectable Triple Negative Breast Cancer
|
Phase 2 | |
| Terminated |
NCT05198843 -
Testing an Omega-3 Fatty Acid-Based Anti-Cancer Therapy for Patients With Triple-Negative Inflammatory Breast Cancer That Has Spread to Other Parts of the Body
|
Phase 1/Phase 2 | |
| Active, not recruiting |
NCT04514484 -
Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV
|
Phase 1 | |
| Recruiting |
NCT05751668 -
Finding an Effective Dose of GM1 to Reduce or Prevent Neuropathy (Numbness or Weakness) Due to Treatment With Paclitaxel (Phase II)
|
Phase 2 | |
| Suspended |
NCT04906369 -
Optimizing Treatment of Stage IV Breast Cancer Through Real-Time Disease Monitoring
|
||
| Completed |
NCT03291938 -
IACS-010759 in Advanced Cancers
|
Phase 1 | |
| Recruiting |
NCT04314401 -
National Cancer Institute "Cancer Moonshot Biobank"
|